Wells Fargo & Company Atossa Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 53,065 shares of ATOS stock, worth $85,965. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,065
Previous 921
5661.67%
Holding current value
$85,965
Previous $1,000
6200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ATOS
# of Institutions
85Shares Held
25.8MCall Options Held
404KPut Options Held
83.6K-
Black Rock Inc. New York, NY9.2MShares$14.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.49MShares$10.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.81MShares$4.56 Million0.0% of portfolio
-
State Street Corp Boston, MA1.66MShares$2.69 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.55MShares$2.51 Million0.0% of portfolio
About ATOSSA THERAPEUTICS, INC.
- Ticker ATOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,624,000
- Market Cap $205M
- Description
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...